Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
19.95
-0.20 (-0.97%)
Delayed Quote
Updated: 1:58 PM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
March 28, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...
Via
Finterra
Topics
Economy
Initial Public Offering
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026
March 25, 2026
As of March 25, 2026, Grifols S.A. (NASDAQ: GRFS) stands at a pivotal crossroads in its century-long history. Once the undisputed champion of the European healthcare sector, the Spanish plasma giant...
Via
Finterra
Topics
Bankruptcy
Economy
Lawsuit
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
March 18, 2026
As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
March 02, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
February 19, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
February 10, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda (TAK) Q2 2025 Earnings Call Transcript
↗
February 05, 2026
Takeda (TAK) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
January 29, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
January 22, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...
Via
MarketMinute
Topics
Economy
Intellectual Property
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
January 01, 2026
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...
Via
MarketMinute
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
December 23, 2025
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...
Via
MarketMinute
Topics
Intellectual Property
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
December 18, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 06, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies
↗
November 21, 2025
The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said.
Via
Stocktwits
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
↗
November 11, 2025
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
Via
Benzinga
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
November 10, 2025
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...
Via
TokenRing AI
Topics
Artificial Intelligence
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
November 07, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....
Via
MarketMinute
Topics
Intellectual Property
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
November 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
↗
October 30, 2025
Takeda posts lower Q2 earnings and trims 2025 outlook as Vyvanse generics, FX headwinds, and impairment charges weigh on revenue and profit.
Via
Benzinga
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
October 30, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
October 27, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
